NCIC CTG CE.6/TROG 08.02 - GBM in Elderly Patients

By w.paterson
15 August, 2021
0 Comments

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

Primary Sponsor

NCIC Clinical Trials Group (NCIC CTG)

Geoff Zipper - aka Swamp - on the Kokoda Trail

26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

AGITG/TROG 21.03 – RESOLUTE

Related Post

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements

NCIC CTG CE.6/TROG 08.02 – GBM in Elderly Patients

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

AGITG/TROG 21.03 – RESOLUTE

Related Post

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements